EGFR mutation-positive NSCLC
Oncology · 2019–2019
1decision
1medicine
1carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| osimertinib First-line treatment of locally advanced (Stage IIIB) or metastatic (Stage IV) epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung… | Jul 2019 | Not recommended | 10 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.